Valerio Zoli

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial

Andrea Gallamini, Francesco Zaja, Caterina Patti et al. · Blood · 2007 · 308 citations · Full text

Medicine, Oncology, Chemotherapy +9

Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma

Corrado Tarella, Roberto Passera, Michele Magni et al. · Journal of Clinical Oncology · 2010 · 167 citations · Full text

Medicine, Hematology, Oncology +16

Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

Giacomo Boffa, Luca Massacesi, Matilde Inglese et al. · Neurology · 2021 · 81 citations · Full text

Medicine, Neurology, Cell Therapy +13

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas

Sergio Cortelazzo, Corrado Tarella, Alessandro M. Gianni et al. · Journal of Clinical Oncology · 2016 · 78 citations · Full text

Medicine, Oncology, Chemotherapy +13

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

Corrado Tarella, Manuela Zanni, Massimo Di Nicola et al. · Leukemia · 2007 · 70 citations

Medicine, Hematology, Oncology +13